Xbrane Biopharma AB (publ) (STO:XBRANE)
| Market Cap | 213.27M +9.1% |
| Revenue (ttm) | 127.95M -38.8% |
| Net Income | -62.68M |
| EPS | -3.04 |
| Shares Out | 20.61M |
| PE Ratio | n/a |
| Forward PE | 8.19 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 34,531 |
| Open | 10.65 |
| Previous Close | 10.65 |
| Day's Range | 10.35 - 11.40 |
| 52-Week Range | 5.42 - 20.00 |
| Beta | 0.70 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 30, 2026 |
About Xbrane Biopharma AB
Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. It offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults. The company also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated... [Read more]
Financial Performance
Financial StatementsNews
Xbrane Biopharma AB Slides: Q4 2026
Xbrane Biopharma AB has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on February 19, 2027.
Xbrane Biopharma AB Transcript: BioStock Life Science Summit 2026
FDA-approved Lucamzi is being prepared for a mid-2027 U.S. launch, while Xdivane's pivotal trial is fully recruited with Q2 2027 readouts expected. Xdivane targets launch at the U.S. patent expiry in Dec. 2028; Xdarzane is earlier-stage.
Xbrane Biopharma AB Earnings Call Transcript: Q3 2026
LUCAMZI’s FDA approval advances a planned 2027 U.S. launch, while Xdivane’s trial is fully recruited and XIMLUCI shipments resumed. Cash was SEK 37.4m, with Fenja refinancing and Valorum financial terms still under discussion.
Xbrane Biopharma AB Quarterly report: Q3 2026
Xbrane Biopharma AB has published its Q3 2026 quarterly earnings report on October 30, 2026.
Xbrane Biopharma AB Slides: Q3 2026
Xbrane Biopharma AB has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 30, 2026.
Xbrane Biopharma AB Earnings Call Transcript: Q2 2026
Ximluci maintained a 7% market share in Europe with resumed shipments and SEK 46.8 million in Q2 revenue. Production cost reductions are expected to take effect from mid-2027, and FDA approval for U.S. launch is pending. Cash position is sufficient for ongoing operations.
Xbrane Biopharma AB Quarterly report: Q2 2026
Xbrane Biopharma AB has published its Q2 2026 quarterly earnings report on July 17, 2026.
Xbrane Biopharma AB Slides: Q2 2026
Xbrane Biopharma AB has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 17, 2026.
Xbrane Biopharma AB Earnings Call Transcript: Q1 2026
Ximluci achieved SEK 17.3 million in Q1 revenue and 8% market share in Europe, with ongoing cost reduction efforts amid price competition. Xdivane development is on track, with new financing terms and a potential SEK 10 billion profit sharing over 10 years.
Xbrane Biopharma AB Quarterly report: Q1 2026
Xbrane Biopharma AB has published its Q1 2026 quarterly earnings report on May 5, 2026.
Xbrane Biopharma AB Slides: Q1 2026
Xbrane Biopharma AB has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 5, 2026.
Xbrane Biopharma AB Earnings Call Transcript: Q4 2025
Ximluci saw strong year-over-year growth and profit contribution, but faces increased price pressure and competition in Europe. Cost reduction measures and FDA resubmission are key focuses, while Xdivane development remains on track for a 2027 US launch.
Xbrane Biopharma AB Annual report: Q4 2025
Xbrane Biopharma AB has published its Q4 2025 annual report on February 20, 2026.
Xbrane Biopharma AB Quarterly report: Q4 2025
Xbrane Biopharma AB has published its Q4 2025 quarterly earnings report on February 20, 2026.
Xbrane Biopharma AB Slides: Q4 2025
Xbrane Biopharma AB has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 20, 2026.